TIDMSUN
RNS Number : 3320Z
Surgical Innovations Group PLC
14 March 2017
Surgical Innovations Group plc
("SI", "the Company" or the "Group")
Final results for the year ended 31 December 2016
Surgical Innovations Group plc (AIM: SUN), the designer and
manufacturer of innovative medical technology for minimally
invasive surgery, reports strong results for the year ended 31
December 2016. In a breakout year for the Group, results were ahead
of market expectations and the balance sheet moved to a healthy net
cash position with ample unutilised banking facilities.
Highlights:
-- Healthy export-led revenue growth - up 11% to GBP6.09m (2015: GBP5.47m)
-- Gross margins restored to within target range to 33.8% (2015: 14.0 %)
-- Adjusted EBITDA of GBP1.41m (2015: GBP0.24m)
-- Operating profit of GBP0.47m (2015: operating loss of GBP1.98m) at operating margin of 7.7%
-- Profit before tax of GBP0.28m (2015: loss of GBP2.13m)
-- Earnings per share of 0.15 pence (2015: loss per share of 0.42 pence)
-- Strong cash generation from operating activities of GBP2.85m (2015: GBP1.51m)
-- GBP1m loan notes converted to equity in December 2016
-- Moved to net cash position of GBP0.72m (2015: net debt of GBP2.26m)
-- New products in pipeline for 2017, including those acquired
through Surgical Dynamics in Nov 2016
Executive Chairman, Nigel Rogers, said: "Management have now
demonstrated a track record of financial success, and built a
robust platform for future development of the business.
"Recent regulatory changes have increased barriers for new
market entrants, and strengthened the market position of those with
the skills and experience to meet more stringent requirements.
"Our core market in laparoscopic surgery is not completely
immune from the effects of economic uncertainty, but health
spending in this area in the UK and other developed markets is
forecast to continue to grow ahead of inflation. We aim to
outperform the sector as a whole by increasing market penetration
through opening new territories and introducing additional products
and ranges, both organically and through additional partnerships
and carefully selected acquisition activity."
This announcement includes inside information as defined in
Article 7 of the Market Abuse Regulation No.596/2014 and is
disclosed in accordance with the Company's obligations under
Article 17 of those Regulations.
For further information please contact:
Surgical Innovations Group plc www.sigroupplc.com
Nigel Rogers, Executive Chairman Tel: 0113 230 7597
Melanie Ross, COO & CFO
WH Ireland Limited (NOMAD & Broker) Tel: 0113 394 6600
Tim Feather
Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com
Relations)
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
Chairman's Statement
The Group is pleased to report strong results in 2016, with
profitability ahead of market year-end expectations. The Group
returned to profitability at the pre-tax level and increased cash
generation, resulting in a positive cash position at the
year-end.
Robust top line growth has been achieved by leveraging the
strong relationships with distributors, as well as fostering
associations in new territories. Gross margins improved
considerably in the year, following a strong second half in 2015.
This resulted from a return to normal manufacturing output as stock
levels regularised. Cost control has been a key focus, enabling the
business to deliver improved profitability and cash generation
during the year.
In the final quarter of the year, the bank debt put in place at
the end of 2014 was repaid. This was considerably earlier than the
November 2017 due date. The loan note holders also converted the
notes into shares during this period. The strong cash generation of
the Group meant that the business closed the financial year with
net cash of GBP0.72m (2015: net debt of GBP2.26m).
Brand identity, innovation and global reach
The SI Brand was further enhanced in the year by the
much-anticipated launch of the Yelloport(TM) Elite range, a new
port access system utilising universal seal technology giving
significantly improved performance for surgeons and theatre staff.
The Group remains focused on innovation and development of its
portfolio of products, brand recognition and the identification of
as yet unmet clinical needs in order to drive the product roadmap
effectively.
The distribution network has continued to expand in 2016 with
the addition of five new territories. There are more potential
distributors in the pipeline who are currently going through the
required regulatory and compliance processes in order to join our
distribution network in the coming year.
Financial Overview
Revenue increased by 11% to GBP6.09m (2015: GBP5.47m), with
growth in branded product sales up by 11% to GBP4.66m (2015:
GBP4.18m) and Precision Engineering also generating significantly
increased activity with revenue of GBP0.21m (2015: GBP0.05m).
Reported gross margins have continued to show substantial
improvement as a result of operational gearing and foreign exchange
gains.
Adjusted EBITDA for the full year (being profit before taking
account of exceptional costs, interest, depreciation, amortisation
and taxation) amounted to GBP1.41m, showing strong growth against
GBP0.24m in 2015. The net operating profit for the year was
GBP0.47m (2015: loss of GBP1.98m). There were no exceptional costs
in the year (2015: GBP1.29m). The net profit and total
comprehensive income for the year amounted to GBP0.72m (2015: loss
of GBP2.03m), after a taxation credit of GBP0.44m (2015: GBP0.09m),
resulting in earnings per share of 0.15p (2015: loss of 0.42p).
At the end of the year, the Group had returned to a positive
cash position of GBP0.72m (2015: net indebtedness of GBP2.26m). The
Group had available cash resources of GBP0.78m with additional
headroom of GBP1.3m of unused facilities, and was in compliance
with all financial covenants.
People
SI has continued to invest in our people and their training.
Amongst other initiatives we have undertaken in 2016 is a year-long
programme of lean manufacturing training for all employees which is
already delivering improvements throughout the business. Employee
numbers have increased, predominantly strengthening manufacturing,
assembly and production engineering which all reflect the increased
manufacturing output.
Current trading and outlook
Trading results for the first two months of the current year
have shown further increases in revenue and profitability compared
with the corresponding period last year.
The overall market for minimally invasive surgical products is
cost competitive, however it is also forecast to grow at an annual
rate of 6.5% in the medium term. We continue to seek opportunities
to exceed this rate of revenue growth by increased market share
through product range development, high levels of customer service
and opening new sales territories.
We also continue to evaluate further opportunities to enhance
our product range and market penetration by forging strategic
partnerships, including potential acquisition of carefully selected
complementary businesses.
Nigel Rogers
Executive Chairman
14 March 2017
Surgical Innovations Group plc
Strategic Report
Whilst the Group's core strategy remains the sale of branded
laparoscopic instrumentation, we have recently seen a shift away
from the sole development and manufacture of these devices in-house
and reached out to selected partners who have demonstrated the
ability to work with SI to offer novel solutions in areas of
instrumentation where SI has not traditionally operated. One of the
first products to come out of this new direction was launched in
early 2017. This has enabled SI to begin offering a range of
ligation products to complement the existing product portfolio. We
are conscious of the fact that the reputation of the Group is built
upon our ability to offer surgeons instruments of high quality at
reasonable prices. We are now in an era when there is increasing
pressure on the costs of healthcare leading to ever more careful
scrutiny of prices by purchasing authorities worldwide. Our
strategy is to concentrate on the development or acquisition of
instruments that surgeons tell us that they need and to introduce
efficiency and innovation into the manufacturing process to enable
us to provide them at competitive prices.
In November 2016, the Group completed the acquisition of the
laparoscopic instruments business and related assets of Surgical
Dynamics Limited. This transaction brought not only new products to
the SI portfolio but also specialist production processes including
metal injection moulding of device components. The assets have now
been transferred into the SI site and machining trials are
underway.
The Group has continued to foster excellent relationships with
our distribution network, engaging our partners through involvement
in product development, supporting them in end user trials and
gathering with them at several conferences and exhibitions
throughout the year. This included a new product launch conference
at the Medica trade show in Germany in the last quarter of the 2016
which garnered strong positive feedback on both the new products
emerging from SI as well as our performance as a partner. The Group
recognises the value in this feedback and relationship and will
continue to exceed our customers' expectations in 2017.
The Group continues to work closely with strategic partnerships
on OEM projects which challenge our Design and Development teams
and complement the core competencies that the Group
demonstrates.
The greater emphasis placed on new product introduction
culminated in the launch of the Yelloport (TM) Elite range in the
final quarter of 2016, this will be followed by further additions
to this range in Q2 2017 as well as two more projects launching
before the end of H1. The Group is excited to be able to offer
these products to the market and remains committed to expanding the
portfolio of products available further in 2017 and beyond.
The Group has continued to deliver against a backdrop of a
challenging economic climate, but by offering consistently high
customer service levels, excellent products and being adaptable in
the face of market and customer feedback, the Board believes the
business is well placed to continue to deliver value to the
shareholder base.
Operating and Financial Review
Revenues
Group revenues increased by 11% to GBP6.09m (2015: GBP5.47m)
demonstrating the ongoing focus of the organisation in improving
and expanding its distributor relationships.
GBPm 2016 2015 % change
----------- ------ ------ ----------
SI Brand 4.66 4.18 +11%
OEM 1.22 1.24 -2%
PE 0.21 0.05 +320%
----------- ------ ------ ----------
Total 6.09 5.47 +11%
----------- ------ ------ ----------
SI Brand
SI Brand sales rose by 11% to GBP4.66m (2015: GBP4.18m) with the
strongest growth areas being sales to the US and Rest of the
World.
Strong growth in the US has come both from the success of the
additional distributor engaged at the beginning of the fiscal year,
the continued efforts of the incumbent distributor and from gains
in exchange as the US dollar moved more favorably against the
Sterling.
OEM
OEM sales remained broadly in line with the prior year at
GBP1.22m (2015: GBP1.24m). Although underlying sales from
continuing relationships continue to grow strongly, these were
offset by agreements which ended by mutual consent in 2015 and were
not repeated in 2016. Although impacting the overall turnover of
the OEM business negatively in the period, the conclusion of these
agreements delivered a margin uplift as the non-repeated sales were
low or no margin business.
Precision Engineering (PE)
The Group undertook further PE projects in the period adding
GBP0.21m to turnover (2015: GBP0.05m). Revenue from this segment is
unpredictable, but the Group remains interested in this field and
continues to work with new and existing partners to identify
innovative projects on which to collaborate.
Gross margin
Gross margin improved significantly, reaching 33.8% (2015:
14.0%) overall in the year, but delivering 41% in the second half,
demonstrating that the production was more in line with demand as
the stock levels normalised somewhat in comparison to the over
stocking in prior years.
Operating expenses
Excluding exceptional items in the prior year, operating
expenses increased to GBP1.59m (2015: GBP1.45m), resulting from an
increase in headcount and annual performance related bonus
costs.
Adjusted EBITDA and operating profit
The adjusted EBITDA is a key performance measure of the
business. The Group uses this as a proxy for understanding the
underlying performance of the Group. This measure also excludes the
items that distort comparability.
The Group achieved a positive adjusted EBITDA of GBP1.41m for
2016, against a comparable adjusted EBITDA (before exceptional
items) of GBP0.24m in 2015. Operating profit for the year was
GBP0.47m (2015: loss of GBP1.98m), reflecting the trade of the
Group and there were no exceptional items in the year (2015:
GBP1.29m).
Finance costs
Interest on bank and finance lease obligations for 2016 resulted
in interest payable of GBP0.19m (2015: GBP0.15m). Due to the
payback of the loan and the conversion of the loan notes in the
final quarter of 2016, the finance costs going forward will be much
reduced.
Taxation
The Group recorded a corporation tax credit of GBP0.44m (2015:
GBP0.09m) and a deferred tax credit of GBPnil (2015: GBPnil). In
overall terms the Group has substantial tax losses on which it
continues to take a cautious view. Consequently the losses have not
been recognised and result in an overall effective rate of tax of
157.7% credit (2015: 4.3% credit). During 2016 the Group submitted
enhanced Research and Development claims in respect of 2014 and
2015, electing to exchange tax losses for cash refunds totaling
GBP0.44m which were received in June and December 2016.
Intangible and tangible assets
Capitalised development costs at 31 December 2016 increased
slightly to GBP1.47m (2015: GBP1.36m) reflecting the focus placed
on new product development, whilst controlling those costs
appropriately. Research and development expenditure continues to be
incurred, and a portion has been capitalised in respect of
specifically identifiable products amounting to GBP0.44m (2015:
GBP0.27m). These products are due for launch in the current
year.
Capital expenditure on tangible assets continued to reflect a
policy of required replacement only during the year at GBP0.16m
(2015: GBP0.17m) and there are no major capex plans currently under
consideration.
In addition during the period the Group acquired certain trade
and assets of Surgical Dynamics Limited for GBP0.36m, which
included intangible assets of GBP0.23m being recognised.
Working capital
Working capital further reduced by GBP0.97m to GBP2.04m (2015:
GBP3.01m). The continued focus on cash and rebalancing the business
drove the stock reduction by a further 22% to GBP1.50m (2015:
GBP1.92m), whilst current trade receivables reduced to GBP1.10m
(2015: GBP1.30m), despite 11% growth in turnover. Trade creditors
reduced to GBP0.34m (2015: GBP0.41m) as the business focused on
reducing costs and harnessing its increased buying power to
negotiate better terms as manufacturing activity increased. This is
expected to increase in 2017 in line with the rise in spending on
materials to support increased manufacturing activity as new
products are brought online and additional stock holding is
required, though not to the levels seen in previous years.
Cash flow, financing and net debt
The Group generated cash from operations of GBP2.40m (2015:
GBP1.58m) primarily as a result of the working capital movements
described above. Cash used in investment was GBP0.78m (2015:
GBP0.45m) resulting in a cash inflow before financing of GBP2.00m
(2015: GBP1.06m).
This inflow was utilised by the business to facilitate early
repayment of the term loan put in place in 2014. This loan was
originally due for repayment in November 2017, but the business was
in a position to repay this debt early and so in conjunction with
the bank, transitioned to a rolling credit facility of GBP1.30m to
be drawn down as the business requires. None of this facility had
been drawn down by the year-end.
At 31 December 2016, total gross indebtedness was GBP0.05m
(2015: GBP3.24m) and the Company had available cash resources of
GBP0.78m (2015: GBP0.98m).
Going concern
The Directors have prepared forecasts for the period to March
2018, which demonstrate a positive cashflow. The Group have access
to banking facilities, which comprise of a committed GBP1.30m
revolving credit facility. Hire purchase agreements are utilised
where required. The commitment of the revolving credit facility of
GBP1.30m may be used towards meeting the Group's general working
capital and other commitments. It is subject to compliance with
financial covenants which measure the ratio of cashflow to debt
service and EBITDA starting quarterly from December 2016.
Based on the forecasts, the Board has a reasonable expectation
that the Company and the Group have adequate resources to continue
in operational existence for the foreseeable future. The Board has
also concluded that there are no material uncertainties and that
the going concern basis should be adopted in preparing these
financial statements.
Melanie Ross
Chief Finance Officer
14 March 2017
Consolidated statement of comprehensive income
for the year ended 31 December 2016
2016 2015
Notes GBP'000 GBP'000
------------------------------------------------ -------------- --------------- ----------------
Revenue 2 6,089 5,468
Cost of sales (4,029) (4,704)
================================================ ============== =============== ================
Gross profit 2,060 764
Other operating expenses 3 33 (1,591) (2,739)
Adjusted EBITDA 1,408 242
Exceptional items - (1,290)
Amortisation of intangible assets (429) (426)
Depreciation of tangible assets (510) (501)
------------------------------------------------ -------------- --------------- ----------------
Operating profit/(loss) 3 469 (1,975)
Finance costs 5 (192) (153)
Finance income 6 1 3
================================================ ============== =============== ================
Profit/(loss) before taxation 278 (2,125)
Taxation credit 7 438 92
================================================ ============== =============== ================
Profit/(loss) and total comprehensive deficit 716 (2,033)
================================================ ============== =============== ================
Profit/(loss) per share, total and continuing
Basic 8 0.15p (0.42)p
Diluted 8 0.14p (0.42)p
================================================ ============== =============== ================
The Consolidated statement of comprehensive income above relates to
continuing operations.
Adjusted EBITDA is defined as earnings before interest,
taxation, depreciation, amortisation and exceptional items.
Consolidated statement of changes in equity
for the year ended 31 December 2016
Share Share Capital Retained
capital premium reserve earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
-------------------------------------- ------- ------- ------- ---------- -------------
Balance as at 1 January 2015 4,851 1,634 329 (695) 6,119
Employee share-based payment options - - - (175) (175)
Equity placing for cash proceeds 12 7 - - 19
------- ------- ---------- -------------
Total - transactions with owners 12 7 - (175) (156)
Loss and total comprehensive income
for the period - - - (2,033) (2,033)
-------------------------------------- ------- ------- ------- ---------- -------------
Balance as at 31 December 2015 4,863 1,641 329 (2,903) 3,930
Employee share-based payment - - - 23 23
Equity issues 471 698 - - 1,169
-------------------------------------- ------- ------- ------- ---------- -------------
Total - transactions with owners 471 698 - 23 1,192
Profit and total comprehensive income
for the period - - - 716 716
-------------------------------------- ------- ------- ------- ---------- -------------
Balance as at 31 December 2016 5,334 2,339 329 (2,164) 5,838
-------------------------------------- ------- ------- ------- ---------- -------------
Consolidated balance sheet
at 31 December 2016
2016 2015
GBP'000 GBP'000
==================================================== ========== ===========
Assets
Non-current assets
Property, plant and equipment 1,579 1,827
Intangible assets 1,597 1,361
3,176 3,188
==================================================== ========== ===========
Current assets
Inventories 1,496 1,916
Trade receivables 1,098 1,301
Other current assets 289 389
Cash at bank and in hand 775 976
==================================================== ========== ===========
3,658 4,582
==================================================== ========== ===========
Total assets 6,834 7,770
==================================================== ========== ===========
Equity and liabilities
Equity attributable to equity holders of the parent
company
Share capital 5,334 4,863
Share premium account 2,339 1,641
Capital reserve 329 329
Retained earnings (2,164) (2,903)
==================================================== ========== ===========
Total equity 5,838 3,930
==================================================== ========== ===========
Non-current liabilities
Borrowings - 2,982
Obligations under finance leases 8 62
Deferred tax liabilities - - -
==================================================== ========== ===========
8 3,044
==================================================== ========== ===========
Current liabilities
Trade and other payables 337 408
Obligations under finance leases 45 196
Accruals 606 192
==================================================== ========== ===========
988 796
==================================================== ========== ===========
Total liabilities 996 3,840
==================================================== ========== ===========
Total equity and liabilities 6,834 7,770
==================================================== ========== ===========
Consolidated cash flow statement
for the year ended 31 December 2016
2016 2015
GBP'000 GBP'000
--------------------------------------- ------- -------
Cash flows from operating activities
Operating profit/(loss) 469 (1,975)
Adjustments for:
Non-cash exceptional items - 1,152
Depreciation of property, plant and
equipment 510 501
Amortisation of intangible assets 429 426
Share-based payment charge 23 -
Grant income (10) (50)
Foreign exchange 65 6
Decrease in inventories 797 1,586
Decrease in current receivables 178 472
Decrease in payables (61) (538)
--------------------------------------- ------- -------
Cash generated from operations 2,400 1,580
Taxation received 531 -
Interest paid (86) (68)
--------------------------------------- ------- -------
Net cash generated from operating
activities 2,845 1,512
--------------------------------------- ------- -------
Cash flows from investing activities
Payments to acquire property, plant
and equipment (161) (172)
Acquisition of intangible assets (440) (275)
Acquisition of Surgical Dynamics
assets and laparoscopic business (182) -
--------------------------------------- ------- -------
Net cash used in investment activities (783) (447)
Conversion of Loan Notes 2017 - 500
Repayment of bank loan (2,000) (1,000)
Cash received from issue of shares - 19
Repayment of obligations under finance
leases (198) (280)
--------------------------------------- ------- -------
Net cash used in financing activities (2,198) (761)
--------------------------------------- ------- -------
Net (decrease) / increase in cash
and cash equivalents (136) 304
Cash and cash equivalents at beginning
of year 976 678
Effective exchange rate fluctuations
on cash held (65) (6)
--------------------------------------- ------- -------
Cash and cash equivalents at end
of year 775 976
======================================= ======= =======
Notes to the consolidated financial statements
1. Group accounting policies under IFRS
Basis of preparation
The audited financial statements have been prepared on the basis
of the IFRS accounting policies set out herein. The financial
statements have been prepared in accordance with IFRS as adopted
for use by the European Union, including IFRIC interpretations, and
in line with those provisions of the Companies Act 2006 applicable
to companies reporting under IFRS. The preparation of financial
statements in conformity with IFRS requires the use of certain
critical accounting estimates. It also requires management to
exercise its judgement in the process of applying the Group's
accounting policies. The financial statements have been prepared
under the historical cost convention, are presented in Sterling and
are rounded to the nearest thousand.
The Directors have considered the available cash resources of
the Group and its current forecasts and are satisfied that the
Group has adequate resources to continue in operational existence
and that there are no material uncertainties casting doubt over the
going concern status of the Group. Accordingly, the financial
statements are prepared on a going concern basis.
The following Adopted IFRSs have been issued but have not been
applied by the Group in these financial statements. Their adoption
is not expected to have a material effect on the financial
statements:
-- IFRS 9 Financial Instruments (effective date 1 January 2018).
-- IFRS 15 Revenue from Contract with Customers (effective date 1 January 2018).
-- IFRS 16 Leases (effective date 1 January 2019).
The financial information set out in this preliminary
announcement does not constitute the Company's Consolidated
Financial Statements for the financial years ended 31 December 2016
or 31 December 2015 but are derived from those Financial
Statements. Statutory Financial Statements for 2015 have been
delivered to the Registrar of Companies and those for 2016 will be
delivered following the company's AGM. The auditors, KPMG LLP, have
reported on those financial statements. Their reports were
unqualified, did not draw attention to any matters by way of
emphasis without qualifying their report and did not contain
statements under Section 498(2) or (3) of the Companies Act 2006 in
respect of the financial statements for 2015 or 2016.
The Statutory accounts will be available on the Company's
website at www.siggroupplc.com with effect from 14 March 2017 and
will be posted to selected shareholders at the end of April.
Shareholders wishing to request a copy can contact the Company's
registered office.
2. Segmental Reporting
Geographical analysis of revenues
2016 2015
GBP'000 GBP'000
--------------- ------- -------
United Kingdom 1,920 1,922
Europe 1,287 1,286
US 1,876 1,539
Rest of World 1,006 721
--------------- ------- -------
6,089 5,468
--------------- ------- -------
Revenues are allocated geographically on the basis of where
revenues were received from and not from the ultimate final
destination of use. During 2016 GBP1,235,000 (20.3%) of the
Group's revenue depended on one distributor in the SI Brand segment
(2015: GBP1,140,000 (20.8%)).
Sales of goods during 2016 were GBP5,883,000 and sales relating
to services in the UK were GBP206,000.
3. Earnings per ordinary share
Basic earnings per ordinary share
The calculation of basic earnings per ordinary share for the
year ended 31 December 2016 was based upon the profit attributable
to ordinary shareholders of GBP716,000 (2015: loss of GBP2,033,000)
and a weighted average number of ordinary shares outstanding for
the year ended 31 December 2016 of 487,924,227 (2015:
485,070,920).
Diluted earnings per ordinary share
The calculation of diluted earnings per ordinary share for the
year ended 31 December 2016 was based upon the profit attributable
to ordinary shareholders of GBP716,000 (2015: loss of GBP2,033,000)
and a weighted average number of ordinary shares outstanding for
the year ended 31 December 2016 of 494,001,073 (2015:
485,070,920).
No. of shares used in calculation of earnings 2016 2015
per ordinary share ('000s) No. of Shares No. of Shares
Basic earnings per share 487,924 485,071
Dilutive effect of unexercised share options 6,077 -
================================================ ===================== ===========================
Diluted earnings per share 494,001 485,071
================================================ ===================== ===========================
4. Net cash/borrowings
2016 2015
GBP'000 GBP'000
--------------------------------- -------- --------
Total borrowings 53 3,240
Less: cash and cash equivalents (775) (976)
--------------------------------- -------- --------
Net (cash)/debt (722) 2,264
Total equity 5,838 3,930
--------------------------------- -------- --------
Total capital 5,116 6,194
--------------------------------- -------- --------
Bank loan
The sterling bank loan provided by Yorkshire Bank on 17 November
2014, which was due to be repaid November 2017 was subject to
quarterly payments of GBP0.1m, totaling GBP0.3m in the year. On the
22 December 2016 the remaining balance of the term loan of GBP1.70m
was repaid from available cash resources, and the bank has made
available a Revolving Credit Facility (RCF) of up to GBP1.30m for
working capital and other purposes until 31 March 2020.
The RCF is subject to compliance with financial covenants which
measure cash flow to debt service and EBITDA. If the bank loan is
drawdown the rate of interest applicable to each loan for its
interest period will be LIBOR plus 2.8% per annum and it will be
secured by a fixed and floating charge over the assets of the
Group. At the 31 December 2016, no amount was drawndown.
Loan notes 2017
On the 21 December 2016 all of the outstanding unsecured fixed
rate convertible loan notes ("Loan Notes") amounting to GBP1.00m,
together with accrued interest of GBP0.11m were converted into
44,259,178 ordinary shares of 1p each at a conversion price of 2.5p
per share. The Loan Notes were originally created on 17 November
2014 and were repayable on 17 November 2017 unless converted into
equity at an earlier date.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR SFFFUDFWSEDD
(END) Dow Jones Newswires
March 14, 2017 03:00 ET (07:00 GMT)
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Apr 2024 to May 2024
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From May 2023 to May 2024